Journal
NATURE REVIEWS RHEUMATOLOGY
Volume 10, Issue 9, Pages 543-551Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrrheum.2014.105
Keywords
-
Categories
Funding
- Association Lupus France
- SNFMI
- Association Francophone contre la Polychondrite Chronique Atrophiante
- Fondation ARTHRITIS Courtin
- Ministry of Education, Culture, Sports, Science and Technology of Japan
- Japan Science and Technology Agency
Ask authors/readers for more resources
Naturally occurring Foxp3(+)CD25(+)CD4(+) regulatory T (T-REG) cells maintain immunological self-tolerance and prevent a variety of autoimmune diseases, including rheumatic diseases such as rheumatoid arthritis and systemic lupus erythematosus. In animal models of rheumatic disease, autoimmune responses can be controlled by re-establishing the T-cell balance in favour of T-REG cells. Here we discuss three potential strategies for the clinical use of T-REG cells to treat autoimmune rheumatic disease: expansion of self-antigen-specific natural T-REG cells in vivo; propagation of antigen-specific natural T-REG cells ex vivo, by in vitro antigenic stimulation, and subsequent transfer back into the host; or conversion of antigen-specific conventional T cells into T-REG cells in vivo or ex vivo. These strategies require depletion of the effector T cells that mediate autoimmunity before initiating T-REG-cell-based therapies. Immunotherapies that target T-REG cells, and the balance of T-REG cells and autoreactive T cells, are therefore an important modality for the treatment of autoimmune rheumatic disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available